Articles From: Amber Alert GPS Available To AT&T Customers For $129.99 to Ambit Biosciences to Announce Fourth Quarter and full-year 2013 Financial Results


Unlimited Voice, Email Notification System Helps Parents and Children to Stay In Touch DALLAS , Nov.
Sign-up for Amber Alert GPS Available To AT&T Customers For $129.99 investment picks
2014/3/26
Amber Road, Inc. (NYSE: AMBR) , a leading provider of global trade management (GTM) solutions, today announced the closing of its previously announced initial public offering of 8,500,299 shares of its common stock at a price to the public of $13.00 per share, which included 1,108,734 shares issued upon the exercise in full of the underwriters’ option to purchase additional shares.
Sign-up for Amber Road Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Share investment picks
2014/4/10
Amber Road, Inc. (NYSE: AMBR), a leading provider of global trade management (GTM) solutions, today announced that it will report its first quarter 2014 financial results after the U.S. financial markets close on Tuesday, May 13, 2014.
Sign-up for Amber Road Announces Date of First Quarter 2014 Financial Results Release investment picks
By Rogerio Jelmayer SAO PAULO--Companhia de Bebidas das Americas (ABEV, ABEV3.BR), or AmBev, reported a 27% increase in net profit for the fourth quarter, as revenue rose and expenses slightly decreased.
Sign-up for AmBev 4th-Quarter Net Profit Rises 27% to BRL4.75 Billion investment picks
2014/2/26
SAO PAULO , Feb.
Sign-up for Ambev Reports 2013 Fourth Quarter And Full Year Results Under IFRS investment picks
SAO PAULO , July 31, 2013 /PRNewswire/ -- Companhia de Bebidas das Americas – Ambev [BOVESPA: AMBV4, AMBV3; NYSE: ABV, ABVc] announces today its results for the 2013 second quarter.
Sign-up for Ambev Reports 2013 Second Quarter Results Under IFRS investment picks
2013/10/31
SAO PAULO , Oct.
Sign-up for Ambev Reports Third Quarter 2013 Results Under IFRS investment picks
2013/10/31
By Rogerio Jelmayer SAO PAULO--Companhia de Bebidas das Americas (ABV), or AmBev, reported a drop in its third-quarter net profit due to lower beer sales.
Sign-up for AmBev's 3Q Net Profit Drops As Beer Sales Fall investment picks
NEWTON, Mass.
Sign-up for Ambient Corporation Announces Resignation from Board of Directors investment picks
2013/11/20
Facilitates deployment on international partner carrier networks NEWTON, Mass.
Sign-up for Ambient Corporation Expands Vodafone Network Test Certification to Entire Smart Grid Node Family Product Line investment picks
Innovative communications solution uses robust powerline standard on both low and medium voltage lines for metering and more.
Sign-up for Ambient Corporation Launches Dual Modem G3-PLC Data Concentrator investment picks
Ambient Secures Committed Credit Facility NEWTON, Mass.
Sign-up for Ambient Corporation Reports Results for the Second Quarter of 2013 investment picks
2013/9/25
NEWTON, Mass.
Sign-up for Ambient Corporation Retains Financial Advisor to Assist in Evaluating Strategic Alternatives investment picks
2014/1/29
Ambient PLC Module facilitates secure, reliable communication over existing low and medium voltage lines, and minimizes infrastructure and communication costs in hard-to-reach environments SAN ANTONIO , Jan.
Sign-up for Ambient Corporation's Powerline Communications (PLC) Module Improves Communication on Downtown Underground Grid Architectures investment picks
2013/10/16
Communications and Applications Platform facilitates system and device interoperability through adoption of global standard NEWTON, Mass.
Sign-up for Ambient Smart Grid Nodes Implement IEC 61850 for Distribution and Substation Automation investment picks
2014/4/7
Phase I Demonstrates Quizartinib Tolerability in Combination with Chemotherapy SAN DIEGO , April 7, 2014 /PRNewswire/ -- Ambit Biosciences  (Nasdaq: AMBI) , a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the initiation of the Phase 2 cohort of the MD Anderson Cancer Center-sponsored Phase 1/2 study of quizartinib in combination with either 5-azacitidine or low dose cytarabine for previously untreated FLT3-ITD positive acute myeloid leukemia (AML) patients age 60 or older, or FLT3-ITD positive AML patients 18 years of age or older in first relapse.
Sign-up for Ambit Announces Initiation Of Phase 2 Cohort In MD Anderson Sponsored Study Of Quizartinib In AML And High Risk MDS investment picks
2014/4/8
SAN DIEGO , April 8, 2014 /PRNewswire/ -- Ambit Biosciences  (Nasdaq: AMBI) , a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the initiation of the QUANTUM-R Phase 3 clinical trial comparing quizartinib as monotherapy to chemotherapy regimens in relapsed/refractory acute myeloid leukemia (AML) patients with the FMS-like tyrosine kinase-3 (FLT3)-ITD mutation.
Sign-up for Ambit Announces Initiation Of Quizartinib QUANTUM-R Phase 3 Trial investment picks
SAN DIEGO , Oct.
Sign-up for Ambit Announces Participation At 12th Annual BIO Investor Forum investment picks
2014/3/4
SAN DIEGO , March 4, 2014 /PRNewswire/ -- Ambit Biosciences  (Nasdaq: AMBI) , a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the Barclays Global Healthcare Conference to be held at the Loews Miami Hotel in Miami Beach, FL , March 10-13, 2014 .
Sign-up for Ambit Announces Participation At Barclays Global Healthcare Conference investment picks
2014/2/4
SAN DIEGO , Feb.
Sign-up for Ambit Announces Participation At Leerink Global Healthcare Conference investment picks
Four Presentations Including Results of Phase 2b Randomized, Open-Label Study of Lower Doses of Quizartinib in FLT3 ITD Positive Relapsed Refractory Acute Myeloid Leukemia (AML) Patients SAN DIEGO , Dec.
Sign-up for Ambit Announces Presentations At The 55th Annual Meeting Of The American Society Of Hematology (ASH) investment picks
2014/3/20
Quizartinib Phase 3 Trial Expected to Begin in Second Quarter 2014 SAN DIEGO , March 20, 2014 /PRNewswire/ -- Ambit Biosciences (NASDAQ: AMBI) , a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced fourth quarter and full-year operating results for 2013.
Sign-up for Ambit Biosciences Announces Fourth Quarter And Full-Year 2013 Operating Results investment picks
Company Announces Four Oral Presentations and Two Posters Highlighting Quizartinib To Be Presented At The 55th Meeting Of The American Society Of Hematology (ASH) SAN DIEGO , Nov.
Sign-up for Ambit Biosciences Announces Third Quarter 2013 Operating Results investment picks
2014/1/27
SAN DIEGO , Jan.
Sign-up for Ambit Biosciences Appoints Mark Foletta To Board Of Directors investment picks
- Company to Host Conference Call and Webcast at 5:00 p.m. EDT, Today, August 13, 2013 SAN DIEGO , Aug.
Sign-up for Ambit Biosciences Corporation Announces Second Quarter 2013 Operational Results investment picks
2013/12/3
Company to Hold Conference Call and Webcast at 9:00 am ET, Wednesday, December 4, 2013 SAN DIEGO , Dec.
Sign-up for Ambit Biosciences Provides Regulatory Update Following FDA Meeting Regarding Quizartinib (AC220) investment picks
2014/3/6
SAN DIEGO , March 6, 2014 /PRNewswire/ -- Ambit Biosciences  (Nasdaq: AMBI) , a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced it will report fourth quarter and full-year 2013 operational results after closing of the NASDAQ Global Market on Thursday, March 20, 2014 .
Sign-up for Ambit Biosciences to Announce Fourth Quarter and full-year 2013 Financial Results investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Amber Alert GPS Available To AT&T Customers For $129.99 to Ambit Biosciences to Announce Fourth Quarter and full-year 2013 Financial Results
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity